Top

Published in:

01-02-2012 | Review Article

Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Author: Vik Khullar

Published in: International Urogynecology Journal | Issue 2/2012

Abstract

Overactive bladder (OAB) is highly prevalent and associated with considerable impact on patient health-related quality of life (HRQoL). Assessment of HRQoL can reveal the burden of disease and post-intervention improvement. This review aims to highlight the importance of HRQoL assessment and outline the tools available for use in clinical trials and real-world clinical practice. A number of validated measures of HRQoL specific to OAB have been developed, offering greater sensitivity and responsiveness over generic instruments. These condition-specific, multi-dimensional and single-item global questionnaires are particularly useful for the multiple and varied symptoms of OAB, as they reflect the patient’s needs, concerns and values. Measurements for lower urinary tract symptoms, e.g. bladder diaries, are being compared with HRQoL instruments to provide greater understanding of the disease and treatment from the patient’s perspective. Therapeutic interventions to improve OAB symptoms should also be evaluated for their effect on the patient’s HRQoL.

Haylen BT, De Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 21:5–26CrossRef

Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314PubMedCrossRef

Stewart W, Herzog R, Wein A et al (2001) Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 20:406–408

Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD (2009) The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 15:S90–S97PubMed

Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT (2009) Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 10:8PubMedCrossRef

Helfand BT, Evans RM, McVary KT (2010) A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol 57:586–591PubMedCrossRef

Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L (2009) Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 15:S118–S122PubMed

Basra R, Khullar V, Kelleher C (2009) Does long-term treatment of overactive bladder result in clinically meaningful improvement in health related quality of life in real world clinical practice? Neurourol Urodyn 28:Abstract 53

10.

Basra R, Basra H, Khullar V, Kelleher C (2010) Prescribing antimuscarinics for overactive bladder; how many chances to we have to get it right? Neurourol Urodyn 29:Abstract 94

11.

Ballert KN (2010) Under treatment of overactive bladder. J Urol 183:1282–1283PubMedCrossRef

12.

Nicolson P, Kopp Z, Chapple CR, Kelleher C (2008) It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol 13:343–359PubMedCrossRef

13.

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff JW, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766PubMedCrossRef

14.

Rosenberg MT, Newman DK, Tallman CT, Page SA (2007) Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 74(Suppl 3):S21–S29PubMedCrossRef

15.

Rovner ES, Goudelocke CM (2010) Urodynamics in the evaluation of overactive bladder. Curr Urol Rep 11:343–347PubMedCrossRef

16.

Digesu GA, Khullar V, Cardozo L, Salvatore S (2003) Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 22:105–108PubMedCrossRef

17.

Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6:S580–S590PubMed

18.

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101:1388–1395PubMedCrossRef

19.

Tubaro A (2004) Defining overactive bladder: epidemiology and burden of disease. Urology 64:2–6PubMedCrossRef

20.

Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH (2009) Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 15:S98–S107PubMed

21.

Coyne KS, Wein AJ, Tubaro A et al (2009) The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 103(Suppl 3):4–11PubMedCrossRef

22.

Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C (2009) The economic impact of overactive bladder syndrome in six Western countries. BJU Int 103:202–209PubMedCrossRef

23.

Tubaro A, Palleschi G (2005) Overactive bladder: epidemiology and social impact. Curr Opin Obstet Gynecol 17:507–511PubMedCrossRef

24.

Wyman JF, Burgio KL, Newman DK (2009) Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 63:1177–1191PubMedCrossRef

25.

Campbell JC, Gries KS, Watanabe JH, Ravelo A, Dmochowski R, Sullivan SD (2010) Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol 9:18CrossRef

26.

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein DA (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562PubMedCrossRef

27.

Abrams P, Artibani W, Gajewski JB, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 68:17–28PubMedCrossRef

28.

Khullar V, Chapple C, Gabriel Z, Dooley JA (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 68:38–48PubMedCrossRef

29.

Shah S, Nitti V (2009) Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol 11:196–202PubMed

30.

Brubaker L, Chapple C, Coyne KS, Kopp Z (2006) Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 68:3–8PubMedCrossRef

31.

Zinner N, Harnett M, Sabounjian L, Sandage B, Dmochowski R, Staskin D (2005) The overactive bladder-symptom composite score: a composite symptom score of the toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 173:1639–1643PubMedCrossRef

32.

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108PubMedCrossRef

33.

Brazier JE, Harper R, Jones NMB et al (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305:160–164PubMedCrossRef

34.

Feeny DH, Furlong WJ, Torrance GW, Goldsmith CH, Zenglong Z, Depauw S (2002) Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care 40:113–128PubMedCrossRef

35.

Brazier JE, Deverill M, Green C, Harper R, Booth A (1999) A review of the use of health status measures in economic evaluation. Health Technol Assess 3(9):1–164

36.

Basra R, Kelleher C (2007) Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments. PharmacoEconomics 25:129–142PubMedCrossRef

37.

Kelleher CJ, Cardozo L, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374–1379PubMedCrossRef

38.

Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef

39.

Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA (1994) Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 3:291–306PubMedCrossRef

40.

Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14:131–139PubMedCrossRef

41.

Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P (1996) The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 77:805–812PubMedCrossRef

42.

Abrams P, Avery K, Gardener N, Donovan J (2006) The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol 175:1063–1066PubMedCrossRef

43.

Reese PR, Pleil AM, Okano GJ, Kelleher CJ (2003) Multinational study of reliability and validity of the King’s Health Questionnaire in patients with overactive bladder. Qual Life Res 12:427–442PubMedCrossRef

44.

Abrams P, Wein A (1998) The overactive bladder: a widespread but treatable condition. Erik Sparre Medical AB, Stockholm

45.

Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M (2008) Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int 102:208–213PubMedCrossRef

46.

Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH (2004) How much is enough and who says so? The case of the King’s Health Questionnaire and overactive bladder. BJOG 111:605–612PubMedCrossRef

47.

Coyne K, Matza LS (2002) Validation of the perception of bladder condition measure in overactive bladder. Value Health 5 (3):Abstract 277

48.

Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V (2006) Determining the importance of change in the overactive bladder questionnaire. J Urol 176:627–632PubMedCrossRef

49.

Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849–855PubMedCrossRef

50.

Lemack GE, Zimmern PE (1999) Predictability of urodynamic findings based on the Urogenital Distress Inventory-6 questionnaire. Urology 54:461–466PubMedCrossRef

51.

Hagen S, Hanley J, Capewell A (2002) Test–retest reliability, validity, and sensitivity to change of the urogenital distress inventory and the incontinence impact questionnaire. Neurourol Urodyn 21:534–539PubMedCrossRef

52.

Barber MD, Spino C, Janz NK et al (2009) The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. Am J Obstet Gynecol 200:580–587PubMedCrossRef

53.

Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C (2002) Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 77:479–487PubMed

54.

European Agency for the Evaluation of Medicinal Products and Committee for Proprietary Medicinal Products (2002) Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence. European Agency for the Evaluation of Medicinal Products and Committee for Proprietary Medicinal Products, London

55.

Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079–1086PubMedCrossRef

56.

Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS (2005) Test–retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 24:215–225PubMedCrossRef

57.

Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMedCrossRef

58.

Freeman R, Hill S, Millard R, Slack M, Sutherst JR, for the Tolterodine Study Group (2003) Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 102:605–611PubMedCrossRef

59.

Wewers ME, Lowe NK (1990) A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13:227–236PubMedCrossRef

60.

Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M (1997) Issues in the measurement of satisfaction with treatment. Am J Manag Care 3:579–594PubMed

61.

Burgio KL, Goode PS, Richter HE, Locher JL, Roth DL (2006) Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings. Neurourol Urodyn 25:411–417PubMedCrossRef

62.

Atkinson MJ, Sinha A, Hass SL et al (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12PubMedCrossRef

63.

Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P (2008) Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 27:179–190PubMedCrossRef

64.

Kopp Z, Abrams P, Piault E et al (2006) Patient satisfaction in studies of overactive bladder: a generic questionnaire versus a disease specific questionnaire. Neurourol Urodyn 25:56

65.

Zinner N, Kobashi K, Koochaki P, Fix D, Egermark M (2010) Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument. Neurourol Urodyn 30:62–68PubMedCrossRef

66.

Larsson G, Victor A (1988) Micturition patterns in a healthy female population studied with a frequency/volume chart. Scand J Urol Nephrol Suppl 114:53–57PubMed

67.

Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA (1988) The urinary diary in evaluation of incontinent women: a test–retest analysis. Obstet Gynecol 71:812–817PubMed

68.

Cardozo L, Hessdorfer E, Milani R et al (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 102:1120–1127PubMedCrossRef

69.

Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73:14–18PubMedCrossRef

70.

Irwin DE, Milsom I, Kopp Z, Abrams P, on behalf of the EPIC Study Group (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53:1029–1037PubMedCrossRef

71.

Staskin DR, Cardozo L (2009) Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. Int J Clin Pract 63:973–976PubMedCrossRef

72.

Herschorn S, Swift S, Guan Z et al (2010) Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 105:58–66PubMedCrossRef

73.

Wein AJ, Khullar V, Wang JT, Guan Z (2007) Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int 99:360–363PubMedCrossRef

74.

Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti V (2009) Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 20:827–835PubMedCrossRef

75.

Newman D, Aronstein WS, Seifu Y, Larson-Peters A, Mongay L (2010) Managing patients with ‘wet’ overactive bladder: results of pooled studies show efficacy of darifenacin as measured by ‘dry days’. UroToday Int J 3(6). doi:10.3834/uij.1944-5784.2010.12.11

76.

Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178PubMedCrossRef

77.

Coyne KS, Payne C, Bhattacharyya SK et al (2004) The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7:455–463PubMedCrossRef

78.

Staskin DR, Dmochowski RR (2002) Future studies of overactive bladder: the need for standardization. Urology 60:90–93PubMedCrossRef

79.

Quinn P, Goka J, Richardson H (2003) Assessment of an electronic daily diary in patients with overactive bladder. BJU Int 91:647–652PubMedCrossRef

80.

Brown JS, McNaughton KS, Wyman JF et al (2003) Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 61:802–809PubMedCrossRef

81.

Cartwright R, Panayi D, Cardozo L, Khullar V (2010) Reliability and normal ranges for the Patient’s Perception of Intensity of Urgency Scale in asymptomatic women. BJU Int 105:832–836PubMedCrossRef

82.

Nixon A, Colman S, Sabounjian L et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607PubMedCrossRef

83.

Van Kerrebroeck PE, Dmochowski R, FitzGerald MP et al (2010) Nocturia research: current status and future perspectives. Neurourol Urodyn 29:623–628PubMedCrossRef

84.

Abraham L, Hareendran A, Mills IW et al (2004) Development and validation of a quality-of-life measure for men with nocturia. Urology 63:481–486PubMedCrossRef

85.

Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R (2008) Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 24:1583–1591PubMedCrossRef

86.

Zinner N, Noe L, Rasouliyan L, Marshall T, Runken MC, Seifeldin R (2009) Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. Am J Geriatr Pharmacother 7:373–382PubMedCrossRef

87.

Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353–365PubMedCrossRef

88.

Furlong WJ, Feeny DH, Torrance GW, Barr RD (2001) The Health Utilities Index (HUI) system for assessing health related quality of life in clinical studies. Ann Med 33:375–384PubMedCrossRef

89.

Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stohrer M (1998) Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society. Neurourol Urodyn 17:249–253PubMedCrossRef

90.

Basra RK, Wagg A, Chapple C et al (2008) A review of adherence to drug therapy in patients with overactive bladder. BJU Int 102:774–779PubMedCrossRef

91.

DuBeau CE, Khullar V, Versi E (2005) “Unblinding” in randomized controlled drug trials for urinary incontinence: implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn 24:13–20PubMedCrossRef

Title: Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?
Author: Vik Khullar
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 2/2012
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-011-1526-9

At a glance: The STEP trials

Springer Medicine

Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

The role of a surgical learning curve in urethral obstruction following autologous fascial sling: a case-series study

Satisfactory urethral coitus in a patient with vaginal stenosis: case report

The Gräfenberg spot (G-spot) does not exist—a rebuttal of Dwyer PL: Skene’s gland revisited: function, dysfunction and the G spot

The effect of urethral calibration on female primary bladder outlet obstruction

Remote discovery of an asymptomatic bowel perforation by a mid-urethral sling

Reply to: The Gräfenberg spot (G-spot) does not exist – a rebuttal of Dwyer PL: Skene’s gland revisited: function, dysfunction and the G spot